Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

It’s no great sur­prise that RA Cap­i­tal weighed in — again — as the most ubiq­ui­tous ven­ture play­er in pri­vate biotech rounds through 2024. Or that ARCH …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.